Texture analysis from CT in discrimination of pancreaticductal adenocarcinoma and hypovascular pancreaticneuroendocrine neoplasm in the portal-venous phase

Aim: To evaluate the discrimination ability of computed tomography (CT) texture analysis between pancreatic ductal adenocarcinoma(PDAC) and hypovascular pancreatic neuroendocrine neoplasm (PNEN). Materials and Methods: Preoperative CT examinations of 49 patients with pathologically proven PDAC (35) and hypovascular PNEN(14) were evaluated retrospectively. Images in the portal vein phase of each tumor were assessed by two radiologists. Differences intexture features between PDACs and PNENs were analyzed with Mann Whitney-U test and logistic regression analysis. Results: Patients with PNEN (50.4 ± 11.7 y) were significantly younger than the patients with PDAC (62.0 ± 11.1y) (p = 0.002). Nine CTtexture features were found statistically significant between groups. NGLDM and GLZLM texture features showed the best diagnosticperformance on multivariate analysis. Between these parameters, NGLDM_ Busyness showed the best diagnostic performance withthe AUC value of 0.865. Combination of NGLDM_ Busyness and GLZLM_LZLGE improved the diagnostic performance at a significantlevel (AUC = 0.906, 95% CI = 0.747-0.988, p < 0.05). Conclusion: CT texture features of single portal venous phase images may help to discriminate hypovascular PNEN from PDAC.

PDF

___

1. Smith MP. Non-cystic fibrosis bronchiectasis. J.R Coll Physicians Edinb 2011;41:132-9.
2. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-84.
3. Emiralioglu N, Ozturk Z, Yalcin E, et al. Long term azithromycin therapy in patients with cystic fibrosis. Turk J Pediatr 2016;58:34-40.
4. Haworth CS, Bilton D, Elborn JS. Long- term macrolide maintenance therapy in non–cf bronchiectasis: Evidence and questions. Respir Med 2014;108:1397- 408.
5. Anwar GA, Bourke SC, Afolabi G, et al. Effects of long term low dose azithromycin in patients with non-cf bronchiectasis. Respir Med 2008;102:1494-6.
6. Behan L, Dimitrov BD, Kuehni CE, et al. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. Eur Respir J 2016;47:1103-12.
7. Karadag B, Karakoc F, Ersu R, et al. Non-cystic fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005;72:233-8.
8. Amalakuhan B, Maselli DJ, Martinez-Garcia MA. Update in Bronchiectasis 2014. Am J Respir Crit Care Med 2015;192:1155-61.
9. Li AM, Sonnapa S, Lex C, et al. Non- CF Bronchiectasis; does knowing etiology lead to changes in management? Eur Respir J 2005;26:8-14.
10. Satirer O, Yesil AM, Emiralioglu N, et al. A Review of the etiology and clinical presentation of non-cystic fibrosis bronchiectasis: a tertiary care experience. Respir Med 2018;37:35-9.
11. Brower KS, Del Vecchio MT, Aronoff SC. The etiologies on non Cf bronchiectasis in childhood: a systematic review of 989 subjects. BMC Pediatr 2014;10:14-4.
12. Bahceci S, Karaman S, Nacaroglu HT, et al. Changing epidemiology of non-cystic fibrosis bronchiectasis. Turk J Pediatr 2016;58:19-26.
13. Fan LC, Lu HW, Wei P, et al. Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials. BMC Infect Dis 2015;15:160.
14. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non- cystic fibrosis bronchiectasis: a randomised, double-blind, placebocontrolled trial. Lancet 2012;380:660-7.
15. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251-9.
16. Yalcin E, Kiper N, Ozcelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006; 31:49-55.